SCHEMBL2179339

SCHEMBL2179339

CC(C)C(C(=O)O)N1Cc2cc(-c3ccc(NC(=O)Nc4cccc(F)c4)cc3)ccc2C1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 4/20 0.52
THRB P10828 2/20 0.46
LMNA P02545 2/20 0.46
KDR P35968 1/20 0.45
CSGALNACT1 Q8TDX6 1/20 0.45
SDCBP O00560 3/20 0.44
SDC2 P34741 3/20 0.44
TP53 P04637 1/20 0.43
AURKA O14965 1/20 0.43
MAP4K4 O95819 1/20 0.43
LCK P06239 1/20 0.43
MET P08581 1/20 0.43
PDGFRB P09619 1/20 0.43
PIM1 P11309 1/20 0.43
PDGFRA P16234 1/20 0.43
CDK8 P49336 1/20 0.43
PRKX P51817 1/20 0.43
CDK5 Q00535 1/20 0.43
ROCK1 Q13464 1/20 0.43
AURKB Q96GD4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2180590 1.00 DGAT1 (0.52) DGAT1THRBLMNAKDRCSGALNACT1
SCHEMBL2179511 0.93 DGAT1 (0.47) DGAT1THRBLMNASDCBPSDC2
SCHEMBL2180663 0.93 DGAT1 (0.47) DGAT1THRBLMNASDCBPSDC2
SCHEMBL2177864 0.93 KDR (0.49) DGAT1THRBLMNAKDRCSGALNACT1
SCHEMBL2176748 0.93 KDR (0.49) DGAT1THRBLMNAKDRCSGALNACT1
SCHEMBL2179062 0.91 SDCBP (0.48) DGAT1THRBLMNACSGALNACT1SDCBP
SCHEMBL2179055 0.91 SDCBP (0.48) DGAT1THRBLMNACSGALNACT1SDCBP
SCHEMBL2181226 0.91 LMNA (0.51) DGAT1THRBLMNASDCBPSDC2
SCHEMBL2179718 0.91 LMNA (0.51) DGAT1THRBLMNASDCBPSDC2
SCHEMBL2178224 0.90 DGAT1 (0.52) DGAT1LMNAKDRCSGALNACT1SDCBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT DGAT1 1/4885THRB 2612/4885LMNA 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.